Efficacy of once every four week oral minodronate in patients with glucocorticoid-induced osteoporosis after switching from weekly oral bisphosphonate
- Conditions
- Glucocorticoid-induced osteoporosis
- Registration Number
- JPRN-UMIN000013305
- Lead Sponsor
- Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital
- Brief Summary
The proportions of patients responding very satisfactory or satisfactory @week 48: switching group 45.9% vs continuing group 26.8%, difference 19.2% [95%CI 3.8 to 34.5], P=0.016 @week 76: switching group 44.6% vs continuing group 28.2%, difference 16.4% [ 1.0 to 31.8], P=0.040 Change in lumber spine BMD from week 24 @week 48: switching group 0.72% [ 0.00 to 1.44] vs continuing group -0.38% [ -1.31 to 0.56] @week 76: switching group 0.88% [ 0.08 to 1.69] vs continuing group -0.60% [ -1.51 to 0.31]
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 145
Not provided
1) Patients with esophageal dysmortility, such as esophageal constriction or achalasia. 2) Patients who could not stay upright position after taking medicine. 3) Patients who had allergic reaction to bisphosphonate. 4) Patients with hypocalcemia. 5) Patients who is presently breast-feeding, is pregnant, is suspected to be pregnant, or cannot use birth control during the study period. 6) Patients who are receiving bisphosphonate other than oral weekly bisphosphonate, teriparatide, or denosumab. 7) Patients who are planning to receive dental extraction in the enrollment period.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method